Galena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, August 9, 2016
July 26 2016 - 7:05AM
Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of targeted
oncology therapeutics that address major unmet medical needs, today
announced that the Company will report its second quarter 2016
financial results and provide a corporate update on Tuesday, August
9, 2016 after the close of the financial markets. The company
will host a conference call following the announcement at 2:00 p.m.
P.T./5:00 pm E.T. to discuss the financial and business results.
The live webcast will include slides that can be accessed on the
Company's website under the Investors section/Events and
Presentations: http://investors.galenabiopharma.com/events.cfm.
The conference call can be accessed by dialing (844) 825-4413
toll-free in the U.S., or (973) 638-3403 for participants outside
the U.S. The Conference ID number is: 51743330. The archived
webcast replay will be available on the Company's website for one
year.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s
development portfolio is focused primarily on addressing the
rapidly growing patient populations of cancer survivors by
harnessing the power of the immune system to prevent cancer
recurrence. The company’s pipeline consists of multiple
mid-to-late-stage clinical assets, including novel cancer
immunotherapy programs with NeuVax™ (nelipepimut-S) and
GALE-301/GALE-302, and one hematology program, GALE-401. For more
information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(503) 405-8258
rbernarda@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024